Evidence map›Paper›PMID 41802115›Full record

ArticleJournal of vascular research2026

Methyl Palmitate, a Potent Angiotensin Converting Enzyme Inhibitor, Attenuates Vascular Remodeling in L-N

Ashwini Rao, Padmanabha Udupa, Cheryl Rhea Lewis, Geethika Yelleti

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of vascular research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ashwini RaoDepartment of Biochemistry, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, India.
Padmanabha UdupaDepartment of Biochemistry, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, India, padmanabha.udupa@manipal.edu.
Cheryl Rhea LewisCentre for Cardiovascular Pharmacology, Department of Pharmacology, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, India.
Geethika YelletiDepartment of Biochemistry, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

<p>Introduction: Angiotensin converting enzyme (ACE) regulates blood pressure via the renin-angiotensin and bradykinin systems. Though synthetic ACE inhibitors are more effective, they pose several side effects. Methyl palmitate (MP), a natural fatty acid methyl ester with cytoprotective, antioxidant, anti-inflammatory, and vasodilatory properties, is not explored for its ACE inhibitory or antihypertensive potential. This study aimed to investigate the in vitro ACE inhibition of MP and its effect on L-NG-Nitro Arginine Methyl Ester (<sc>L</sc>-NAME)-induced hypertensive male Wistar rats.

methodsAn in vitro ACE inhibition assay was conducted to compare the inhibition potency of MP with that of lisinopril. Male Wistar rats (n = 35, 7 per group) were grouped into control, disease control, and treatment groups receiving 100, 150, or 200 mg/kg/day of MP for 21 days each. Blood pressure, serum ACE activity, malondialdehyde (MDA), and nitric oxide (NO) levels in kidney tissue homogenate, and thoracic aorta histopathology were assessed.

resultsMP inhibited ACE by 61.05% at 5 µ<sc>m</sc>, exceeding lisinopril's 41.67%. High-dose MP significantly reduced serum ACE and MDA levels, while increasing NO (p < 0.001). Histopathology revealed near-normal vasculature, although changes in blood pressure were not statistically significant (p > 0.05).

conclusionMP demonstrates strong natural ACE inhibition, antioxidant, and vascular protective effects, supporting further research for therapeutic optimization. </p>.

Indexed as

Angiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsAorta, ThoracicHypertensionNG-Nitroarginine Methyl EsterPalmitatesVascular RemodelingAnimalsBlood PressureDisease Models, AnimalDose-Response Relationship, DrugKidneyLisinoprilMaleMalondialdehydeNitric OxideAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsLisinoprilMalondialdehydemethyl palmitateNG-Nitroarginine Methyl EsterNitric OxidePalmitatesPeptidyl-Dipeptidase AACE inhibitionAngiotensin converting enzymeBlood pressureMalondialdehydeMethyl palmitateNitric oxide

Identifiers

PMID41802115
PMCPMC13155739

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.